Genetic landscape of Smoldering Myeloma February 2, 2018 - Mark Bustoros, MD, provides insight on prognostic models in smoldering multiple myeloma (SMM) and genetic mutations that are associated with disease progression.
Improving the prediction of progression of multiple myeloma January 23, 2018 - Mark Bustoros, MD from Dana-Farber Cancer Institute discusses on how to improve the prediction of progression of multiple myeloma at the 2017 American Society of Hematology in this Oncology Tube video.
Center of Prevention of Progression of Blood Cancers and PCROWD January 23, 2018 - Mark Bustoros, MD from Dana-Farber Cancer Institute discusses the Center for Prevention of Progression of Blood Cancers and its focus on precursor conditions of blood cancers at the 2017 American Society of Hematology in this Oncology Tube video.
Liquid biopsies in patients with multiple myeloma precursor conditions January 2, 2018 - Mark W. Bustoros, MD, a postdoctoral fellow at Dana-Farber Cancer Institute, Harvard Medical School, discusses ongoing research exploring the use of liquid biopsies in patients with smoldering multiple myeloma in this Targeted Oncology video.
How I Treat Smoldering Multiple Myeloma - Irene M. Ghobrial August 8, 2016 - Dr. Irene Ghobrial discusses smoldering myeloma, a heterogeneous clinical entity where some patients have a very indolent course of disease while others have a more aggressive course. (Chapter 7, How I Treat: A Compendium for the Practicing Hematologist, 2nd Edition)
Irene Ghobrial, MD explains Dana-Farber's CPOP January 15, 2016 - Irene Ghobrial, MD, explains the strategy and need for Dana-Farber’s Center for the Prevention of Progression of Blood Cancers -- a research initiative focused on understanding the progression and evolution of blood cancers, with an aim to develop targeted medicines that will leading to early interventions that can eliminate blood cancers.
Myeloma 2015 round table: Advances in Genomics and Precision Medicine July 23, 2015 - Watch a roundtable discussion on how recent advances in understanding the genomics of myeloma is continuing to impact the effectiveness of treatment strategies and outcomes of patients with myeloma.
Irene M. Ghobrial discusses a Phase I study June 14, 2013 - Watch Dr. Irene Ghobrial speak at the 2013 ASCO Conference on: Phase I Study of TH-302 and Dex in Patients with Relapsed and Refractory Multiple Myeloma.